MedTrace Logo

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

NCT05287360 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-04-18

No results posted yet for this study

Summary

The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.

Conditions

  • Healthy

Interventions

DRUG

Rivoceranib

Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.

Sponsors & Collaborators

  • Elevar Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2022-03-16
Completion
2022-03-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05287360 on ClinicalTrials.gov